- Poster presentation
- Open Access
P014. Migraine and hypnosis
© Ardore et al. 2015
Published: 28 September 2015
Hypnosis is an alternative therapy treatment for those patients who do not want pharmacological therapy or for those who need more therapy to control pain due to migraine attacks. In our study, we evaluated 105 migraine patients randomly selected from those patients treated at the Headache Centre of the University Hospital City of Health and Sciences of Turin and who had shown interest in hypnotherapy, had been diagnosed according to the ICHD-3beta criteria, and had experienced headache days (HD) in the last three months.
We submitted a questionnaire reporting a brief description of hypnosis, proposing the possibility to try this therapy. We obtained informed consent from the patients interested in the study. At a later date, we gathered diagnosis and HD from the patients’ clinical records.
Patients were divided by gender: 50% males and 55% females were responders with a mean of 53%. According to the ICHD diagnostic criteria: 42% of patients with migraine without aura were interested in hypnosis (HI) and 35% were not interested in hypnosis (NHI); migraine with aura: 1% (HI) and 2% (NHI); migraine without and with aura: 7% (HI) and 6% (NHI); chronic migraine: 4% (HI) and 4% (NHI). Analysing HD we found that: 65% of patients with < 3 HD were not interested in trying hypnotic therapy (HT) for migraine treatment; patients with > 30 HD, 78% were interested; patients with > 11 HD, 68% were interested in HT and 32% were not; in patients with < 11 HD, 61% were not interested in HT and 39% showed interested.
We have for the first time an estimate of migraine patients interested in HT regardless of headache diagnosis and gender. There is a 53% probability that a migraine subject could be interested in HT. Taking HD into account, we found a linear correlation between HD and treatment seeking. Patients with > 12 HD or < 12 HD have a 2/3 probability of being or not being interested in HT.
Written informed consent to publication was obtained from the patient(s).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.